Glenmark receives ANDA tentative approval for generic version of Qtern
29 April 2020 | News
Qtern Tablets, 10 mg/5 mg market achieved annual sales of approximately $10.4 million
Source: Shutterstock
Glenmark Pharmaceuticals has been granted tentative approval by the United States Food & Drug Administration for Dapagliflozin and Saxagliptin Tablets, 10 mg/5 mg, the generic version of Qtern Tablets, 10 mg/5 mg, of AstraZeneca AB.
According to IQVIATM sales data for the 12-month period ending February 2020, the Qtern Tablets, 10 mg/5 mg market achieved annual sales of approximately $10.4 million.
Glenmark’s current portfolio consists of 162 products authorized for distribution in the U.S. marketplace and 44 ANDA’s pending approval with the USFDA.
